摘要
Even today,lung cancer remains one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide.Throughout the past decades,remarkable advances have been made in the research and development of anti-lung cancer drugs in China.Since the first registered Chinese clinical trial on May 2,2006,many potent anti-lung cancer drugs have been developed and approved by the China Food and Drug Administration and the National Medical Product Administration of China.Among them,the most advance were observed in the development of targeted agents and immunotherapeutic agents such as epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitors(TKIs)icotinib,aumolertinib,and furmonertinib,anaplastic lymphoma kinase(ALK)-TKI ensartinib,programmed cell death-1(PD-1)monoclonal antibodies(mAbs)camrelizumab,sintilimab,and tislelizumab,and programmed cell death-ligand 1(PD-L1)mAb sugemalimab,which have made huge breakthrough in recent years.Some other investigational innovative drug also demonstrated promising efficacy and acceptable safety profiles.Results from clinical studies on these China innovative drugs have led to changes in clinical practice guidelines and considerably improved the outcomes for patients with lung cancer.Thus,in this review,we aim to provide further insight into the clinical development and achievement of China innovative anti-lung cancer drugs.
基金
This work was supported by the China National Major Project for New Drug Innovation(No.2017ZX09304015).
